Objectives To analyze the rate of remissions in RA pts treated with tocilizumab (TCZ) on self-assessment index.
Methods The study included 42 RA pts, predominantly female, 86% were RF-positive and, 84% - ACCP-positive, mean age 50,5±3,1 y, mean disease duration 5,6±4,74 y., high disease activity was established in 93% patients. Prior to TCZ all pts were receiving DMARDs, mostly methotrexate at average dose 15,0±2,7 mg/week; 14,3% pts - leflunomide 20 mg/day; 11,9% - sulfasalazine 2 g/day for at least 3 months without any improvement. TCZ 8 mg/kg was administered every 4 weeks during 24 weeks. Treatment outcomes were assessed by patients using RAPID-3, DAS28, CDAI, SDAI.
Results Before therapy average RAPID-3 was 15,6 [11,5;18,85]. After first infusion remission by RAPID-3 scale was achieved in 14% patients, at week 12 – in 20,3%, after 16 weeks - in 25%, by week 20 – in 30,5%, by week 24 - in 33,3% patients. After 6 month of TCZ therapy remission or low disease activity was achieved in 61,9% patients. Comparable results in were documented on SDAI (33%), CDAI (31%) and RAPID-3 (33,3%) scales. By week 24 of therapy maximum percentage of remissions was registered by DAS28 (71,4%).
Conclusions Remissions rates on RAPID-3 are similar to SDAI and CDAI, and 2-fold lower than the rates by DAS28 score. The difference in remissions rates is most likely explained by subjective factor in patient's self-assessment using RAPID-3, CDAI and SDAI scales vs physician's oversized assessment of patient's health status using DAS28.
Disclosure of Interest None declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.